Evaluation of skin cancer screening in Germany – participation, tumor detection and interval tumors based on SHI data

• Published in: Journal der Deutschen Dermatologischen Gesellschaft 2023-12, Vol.21 (S5), p.3-11
• Main Authors: Garbe, Claudia, Augustin, Matthias, Augustin, Jobst, Baltus, Hannah, Eisemann, Nora, Hübner, Joachim, Katalinic, Alexander, Wolf, Sandra, Hagenström, Kristina
• Format: Article
• Language: English
• Subjects: Cancer screening; evidence; Medical screening; melanoma; secondary prevention; Skin cancer; Skin tests; Tumors
• ISSN: 1610-0379; 1610-0387
• DOI: 10.1111/ddg.15170

Summary Background and goals The rising incidence of skin cancer in Germany has increased the need for secondary prevention measures. For this purpose, a statutory skin cancer screening for insured persons aged 35 and older was introduced on 1 June 2008. The aim of this work package in the Innovation Fund project “Perspectives of a multimodal evaluation of early skin cancer detection” (Pertimo) was to test an evaluation of skin cancer screening using secondary data. Patients and methods The data basis was statutory insured persons of the DAK Health from the age of 35 who were insured as of 31 December 2010 and were followed up until the end of 2015. The rates of participation, skin tumors detected in skin cancer screening (tumor detections), and interval tumors that occurred within two years after a finding‐free skin cancer screening were calculated. Results The biennial skin cancer screening take‐up rate in 2014 and 2015 was 33.6% for women and 32.6% for men. Of those screened, 4.2% had a skin cancer finding (tumor detection) in the course of skin cancer screening. Of all incident skin cancer diagnoses (2012–2015), 50.1% were detected in skin cancer screening. In 1.5% of the insured persons with skin cancer screening without findings, an incidental skin tumor was diagnosed in the following two years (interval tumor). Conclusions The data from the statutory health insurance mapped the skin cancer screening occurrence in Germany and highlighted the importance of dermatologists in the screening process. The analysis provided important new insights.